GLP-1

Technology is increasingly being used to modify human biology and cognition rather than the external world, as seen in AI tools that reduce cognitive effort and GLP-1 drugs that suppress desire. This …

Eli Lilly reported positive interim Phase 1b data for its in vivo PCSK9 base editor VERVE-102, showing single-dose LDL-C reductions of up to 62% sustained for 18 months in patients with heterozygous f…